News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

3,000+ Patient Meta-Analysis Reinforces Importance of Platelet Reactivity Testing to Aid in Risk Assessment


10/27/2011 12:14:19 PM

SAN DIEGO--(BUSINESS WIRE)--Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that results from a patient-level meta-analysis of more than 3,000 stent patients have been published in the Journal of the American College of Cardiology1. Patients in the study with high platelet reactivity, as measured by the Accumetrics’ VerifyNow P2Y12 Test, exhibited more than twice the rate of cardiovascular death, heart attack and stent thrombosis over 2 years compared to patients without high platelet reactivity. The VerifyNow P2Y12 Test is used to measure a patient’s platelet reactivity and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix® and Effient®).

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES